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Abstract
Health economists have studied the determinants of the expected value of health status
as a function of medical and nonmedical inputs, often finding small marginal effects of
the former. This paper argues that both types of input have an additional benefit, viz.
a reduced variability of health status. Using OECD health data for 24 countries between
1960 and 2004, medical and nonmedical inputs are found to reduce the variability of life
expectancy. While the evidence supports the “flat-of-the-curve medicine” hypothesis with
respect to the expected value of life expectancy and its variability, healthcare expenditure
is comparatively effective in reducing variability.
JEL classification: I10, I12, J10
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1 Introduction and motivation
Industrial countries have been spending a rising share of their economic resources on health-
care. From 1960 to 2004 healthcare expenditure (HCE) of OECD countries increased from 3.8
percent of GDP on average to 8.9 percent. Over the same period, health has improved, with
average life expectancy at birth increasing from 68.4 to 78.5 years. However, this increase has
slowed recently. In the United States, it has been 0.19 percent per annum between 1980 and
2004, down from 0.3 between 1960 and 1980. Since HCE continued to grow at a rate of 7.7
percent between 1980 and 2004, this was often interpreted as evidence of decreasing marginal
returns (“flat-of-the-curve medicine”), raising the question of why citizens and governments
failed to reallocate resources away from medicine.
However, this conclusion may be premature on at least two acounts. The first derives from
the “production of health” concept (Grossman [1972]), which emphasizes nonmedical inputs,
notably individuals’ own efforts at maintaining health. Specifically, Zweifel et al. [2009, ch.
4] argue that possibly individuals reduced health-enhancing efforts or used more unhealthy
consumption goods, thus counterbalancing the positive effect of medical care on life expectancy.
Second, the implicit assumption that individuals only value changes in the expected value of
health status is open to criticism. If people are risk-averse with regard to their health, they are
made better off by a reduction in the variance of health status (Lichtenberg [1998]). Following
up on this second aspect, one is led to ask a few additional questions. How has the variability of
health status developed over time? Can this development be related to inputs to the production
of health? And if so, what is the relative effectiveness of medical vs. nonmedical inputs? This
contribution seeks to provide answers to these questions.
The remainder of this paper is structured as follows. After a literature review in Section 2,
the Gini coefficient is introduced as an indicator of uncertainty with regard to the length of life
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in Section 3. Section 4 is devoted to the econometric specification, the description of the data,
and variable definitions. Estimation results are presented and discussed in Section 5. Section 6
concludes with a summary of key findings and suggestions for future work.
2 Survey of the literature
This survey is in two parts. First, research relating the expected value of health status to
medical and nonmedical inputs is discussed, checking whether the choice of output indicator
matters and which model specification is most appropriate for the model to be estimated in
Section 3. Second, the survey reports on work focusing on the variability of health status and
its determinants. Since this investigation is limited to OECD country data, the review cites
only studies based on aggregate observations.
2.1 Determinants of health status at the aggregate level
At the aggregate level, the choice of output variable in a production function of health is
constrained by data availability. Traditionally, mortality rates and life expectancies have served
as proxies of health status.
In their seminal contribution, Auster et al. [1969] relate age- and sex-adjusted mortality
rates of U.S. states of 1960 to medical inputs (viz. number of physicians, pharmaceutical
outlay, capital stock of hospitals, and medical auxiliary staff), economic factors (income, years
of schooling, and degree of urbanization), factors related to lifestyle (alcohol consumption,
smoking), and organizational factors (share of group practices and medical schools). Schooling
and income tend to reduce mortality rates, but both effects are not significantly different from
zero. Only medical auxiliary staff is found to reduce mortality rates, while physicians seem
to increase it. However, this might be due to reverse causality to the extent that physicians
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work in areas where there is demand for their services, indicated by a high risk of death. In
a two-stage least squares estimation, all medical inputs have the expected sign but are not
significant, suggesting that they are not effective at the margin.
The follow-up study by Thornton [2002] provides more recent evidence for the United States.
It modifies the approach by Auster et al. [1969] in two major ways. First, additional determi-
nants are included (share of married couples and crime rate). Second, in addition to medical
inputs, income is treated as endogenous as well. Using U.S. data for 1990, Thornton [2002] finds
only higher education and married couples to have a significantly negative effect on mortality.
Significantly positive effects emanate from cigarette and alcohol consumption, insignificantly
positive ones, from the crime rate and percent of population employed in manufacturing. With
HCE insignificant, the study confirms the “flat-of-the-curve medicine” hypothesis.
However, studies based on OECD data tend to contradict this hypothesis. Zweifel and Fer-
rari [1992] introduce two changes to the health production function. First, they take remaining
life expectancy at ages 40 and 65 as their dependent variable, arguing that it is especially
longevity in retirement that creates problems for the financing of health care. Second, they
account for lagged HCE per capita (with a lag of 10 years due to data availability) on the
grounds that health status is not so much influenced by current but past medical interventions.
Since health is likely to be exposed to similar unobserved shocks across OECD countries, they
run a seemingly unrelated regression (SURE) on 1980 data. They find a significant elasticity
of remaining life expectancy w.r.t. lagged HCE of 0.11.
Miller and Frech [2000] relate life expectancy at birth, at age 40, and age 60 to pharmaceuti-
cal and non-pharmaceutical HCE, cigarette and alcohol consumption, animal fat consumption,
and the share of women in the population (all variables in logarithms), using 1996 OECD data.
They find that a one percent increase of pharmaceutical expenditure results in a 0.02 percent
increase of remaining life expectancy at the age of 40 and even a 0.04 percent increase at the age
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of 60. Furthermore, the marginal effect of pharmaceutical consumption is greater for females
than for males. By way of contrast, nonpharmaceutical HCE does not seem to have a significant
impact on remaining life expectancy.
Shaw et al. [2005] estimate a health production function using OECD data for the year 2000.
In view of small sample size, they use residual maximum likelihood and estimate a random
effects rather than a fixed effects model (with country dummies).1 An important extension
to previous studies is the inclusion of a country’s age distribution in an attempt to avoid the
problem of reverse causality, with an older population consuming more HCE. When the age
distribution is entered, a one percent increase in pharmaceutical expenditures is estimated to
increase life expectancy at age 40 by 0.03 percent (0 percent otherwise).
In their re-estimation of Zweifel and Ferrari [1992], Zweifel et al. [2005] use an OECD panel
data set. Taking into account that HCE figures may be driven up by mortality (caused by high
HCE of individuals in their last year of life) and testing for the appropriate lag for HCE (which
turned out to be 10 years again), they estimate an elasticity of remaining life expectancy at
age 65 w.r.t. lagged HCE of 0.06 for females and 0.07 for males. However, these values are
dominated by GDP (an indicator of nonmedical inputs), its elasticity being 0.12 and 0.08,
respectively.
Summing up, the “flat-of-the-curve” hypothesis cannot be maintained in its strict sense,
stating that additional medical inputs have no discernible effect on health status in the ag-
gregate. Still, the available evidence suggests that nonmedical inputs may be more effective
than medical ones in improving health of the population at large, calling for a reallocation of
resources e.g. in favor of education to the detriment of health. However, an increasing share of
GDP devoted to the healthcare sector might be justified if individuals not only value higher life
1 Residual maximum likelihood produces unbiased estimates of the conditional variance components by cor-
recting the usual maximum likelihood estimator for the degrees-of-freedom loss associated with estimating
the conditional mean (Patterson and Thompson [1971]).
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expectancy but also a reduced uncertainty of premature death, thanks to HCE. The existing
evidence regarding improved control over one’s health status is summarized in the following
section.
2.2 Evidence on increased control over health status
The ideal of western lifestyle presumably is to live in perfect health, followed by sudden
death. To the extent that individuals are successful in pursuing this ideal, premature death is
avoided, resulting in the well-known rectangularization of the survival curve. The conventional
wisdom is predicated on a biological limit to life. However, this age limit may well move
over time. This calls for a measure of concentration that is invariant to the length of life.
The Gini coefficient satisfies this requirement (see Section 3 below). Yet studies focusing on
the variability of (or conversely, control over) health status have used indicators failing this
requirement, except for the study by Shkolnikov et al. [2003].
Heligman and Pollard [1980] analyze Australia’s age-specific mortality and its development
over time. They distinguish infant mortality, excess mortality among young adults, and “pure”
age-related mortality. They identify a variance parameter in the infant mortality component
and trace the development of this parameter for both genders from 1946 to 1972, concluding that
it decreased more markedly than general age-related mortality. The same method is applied by
the Swiss Federal Statistical Office [1996] to Swiss data. Between 1876 and 1973, the variance
parameter in the infant mortality component decreased sharply for both genders, followed by a
slight increase for females between 1973 and 1993. On the whole the study confirms the result
of Heligman and Pollard [1980].
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Wilmoth and Horiuchi [1999] use the interquartile range 2 of age at death as an indicator
of variability in length of life. Applying this measure to Sweden, Japan, and the United States
they find a marked decrease. Between 1901 and 1995, the interquartile range fell from 46.4 to
15.5 years in Sweden and from 46.9 to 19.1 years in the United States. In Japan it decreased
from 23 to 15.2 years between 1951 and 1995. Whereas the authors attribute the reduction of
variability until the 1950s to lower infant mortality rates, they claim decreased mortality rates
at older ages to be crucial since.
Shkolnikov et al. [2003] use life table information from several industrial countries to esti-
mate differences in longevity. Emphasizing the analogy between the distribution of life years
and income, they favor the Gini coefficient as a concentration measure. The lower the Gini
coefficient, the more equal a distribution; in the present context, this means that x percent of
life years are enjoyed by approximately x percent of the population. Conversely, this implies
that death is heavily concentrated among the aged within a given population. The authors find
marked differences in Gini values between countries, suggesting different degrees of uncertainty
with regard to survival and hence health status.
The present study builds on the work of Shkolnikov et al. [2003] by using the Gini coefficient
as an indicator of health status uncertainty. It follows Heligman and Pollard [1980] by tracing
the development of their indicators for both genders over time. However, it goes beyond these
contributions by asking the question whether this development is related more to medical or
nonmedical inputs to the production of health, thus generalizing the approach adopted by the
literature cited in section 2.1.
2 This is the difference between the ages where the survival curve crosses the third and the first quartile of
the age distribution.
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3 Measuring uncertainty with regard to length of life
The Gini coefficient is traditionally used for the analysis of inequality in the income and
wealth distribution (Atkinson [1970]). It is defined as the area between the diagonal and the
Lorenz curve, divided by the whole area below the diagonal. The Lorenz curve in turn represents
the cumulative income share as a function of the cumulative population share (Lorenz [1970]).
Since the Gini coefficient is mean-independent, it is an ideal indicator for measuring inequality
(or variability, respectively) when the quantity of interest changes over time (Sen [1973], ch. 2).
It is therefore suited to measure variability in the length of life. Following Hanada [1983], the
Gini coefficient can be applied to the length of life as follows. Let x be years lived rather than
income. In order to measure the number of years lived, the person’s death must be observed.





with dxi denoting the number of deaths at age x of cohort i and l0 the number of survivors at
year 0 (the size of the cohort). To simplify the discussion, the following analysis is limited to





It defines the horizontal axis of Figure 1, with n denoting the oldest age in the life table. The
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representing the vertical axis of Figure 1. The Lorenz curve is defined over [0, 1], the range
of Fx. In a situation of perfect equality, the share of the population Fx coincides with its share
in the total of life years lived, Φx. Therefore, the Lorenz curve runs diagonal in this case, from
points (0, 0) to (1, 1). The higher the variability in years lived across a population, the greater
the divergence between the diagonal and the Lorenz curve.
Figure 1 below displays Lorenz curves for Portugal for 1960, 1980, and 2004 based on
the Human Mortality Database [2008]. They approach the diagonal, indicating that more
individuals die around the same age. However, the Lorenz curve can also be interpreted as
an indicator of uncertainty (Davidson [2008]).3 A Portuguese born in 1960 would have faced
a situation of great uncertainty, because about 20 percent of that cohort already died by the
age of 52, or conversely only 80 percent could count on living at least 52 years. By 1980,
the distribution of life years had approached a situation where most people died at the same
age (around age 78). Now, 80 percent of the cohort could count on living at least 62 years,
indicating less uncertainty. And by 2004, 80 percent of the cohort is predicted to live at least
69 years - a prospect that corresponds to an almost perfect rectangularization of the survival
curve.
Recall that the Gini coefficient is defined as the area between the diagonal and the Lorenz
curve divided by the area under the diagonal. Noting that the total area below the diagonal of
Figure 1 is 0.5 and integrating the areas stepwise4, one obtains for the Gini coefficient for the









3 Saying that the Lorenz curve of the distribution F (·) Lorenz dominates the Lorenz curve of the distribution
G(·) is equivalent to saying that F (·) is the less risky distribution.
4 The area between the diagonal and the Lorenz curve can be divided into trapezes.





(Fx − Fx+1)(Fx − Φx + Fx+1 − Φx+ 1). (5)
[Figure 1 about here]
The Gini coefficient varies between 0 (perfect equality and hence minimum uncertainty) and
1 (perfect inequality and hence maximum uncertainty). It is equal to 0 if all individuals of a
cohort die at the same age (live to the same age, respectively) and equal to 1 if everyone dies
at age 0 while one individual dies at the maximum age. Using eq. (5), Gini coefficients are
calculated for 24 countries between 1960 and 2004. Gini coefficients of all countries decrease over
time indicating that variability of age at death declined (see Tables 4 to 6 in the Appendix but
also Figure 2). The maximum drop, from 0.21 in 1960 to 0.10 in 2004, is found for Portugal. The
top and bottom five countries are listed in Figures 4 and 5 (see Appendix) for the years 1960
and 2003. The countries with least variability were all Scandinavian (plus the Netherlands)
in 1960, while Portugal had maximum variability. By 2003, three of the five low-variability
countries were still Scandinavian, while Hungary had taken the place of Portugal, followed by
the United States.
Three more findings are worth mentioning. First, Figure 2 below shows that in 1960, the
Italians, the Portuguese, and the Japanese faced a higher longevity risk than U.S. citizens.
However, this ranking has changed since. By 2004 Americans faced a considerably higher risk
with regard to length of life than the citizens of these countries. Second, the fall of the Gini
coefficients tends to slow down, most visibly in the 1980s (Figure 2 is fairly typical of Tables
4 to 6). Third, Gini coefficients exhibit a similar pattern of decrease for females and males
(see Tables 5 and 6), with a systematic difference in favor of females in all countries sampled,
however.
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[Figure 2 about here]
In all, there is clear evidence suggesting that individuals in industrial countries have been
exposed to less uncertainty regarding their longevity (and presumably health status) since 1960.
This observation naturally gives rise to the question of what may have contributed to better
control over health status. Figure 3 suggests that factors influencing the expected value of
health status (proxied by life expectancy at birth) may also influence its variability (proxied
by the Gini coefficient) since countries with higher life expectancy correspond to countries with
lower Gini coefficients.
[Figure 3 about here]
4 Econometric specification, data, and variable definitions
For the econometric specification it is important to note that observations are available on
the same country, resulting in a panel data set. This calls for an estimating equation of the
following (linear) form,
yit = βxit + ci + uit. (6)
In the present context yit denotes the Gini coefficient of country i in year t, β a vector of coef-
ficients to be estimated, xit a set explanatory variables, , ci a country-specific effect (specified
in more detail below), and uit a stochastic error term. Estimating eq. (6) with pooled ordinary
least squares (OLS) entails two problems. First, the ci component of the error term may be
correlated with elements of xit, resulting in biased estimates of β. Second, neglecting the two
sources of stochastic risk causes OLS to attribute too little of total variance in yit to the error
term. Therefore, eq. (6) is estimated using the fixed effects (FE) or the random effects (RE)
specification. The first consists in making the ci an element of the xit vector by inserting a
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set of country-specific dummies. Alternatively, the ci can be netted out by measuring all vari-
ables as differences from the country-specific means. The second approach assumes the ci to be
stochastic, which means they must be uncorrelated with the xit for unbiased estimation of β.
Moreover, the ci and uit components of the error term are assumed to be uncorrelated as well.
RE is more parsimonious and hence more efficient than FE estimation. A generally accepted
way of choosing between FE and RE is running a Hausman [1978] test. The Hausman test
checks a more efficient model against a less efficient but consistent model to assure that the
more efficient model also gives consistent results (Verbeek [2004], ch. 10).
Four further issues need to be clarified. First, variability of health status may feed back to
HCE, one of the x variables. Countries where individuals face higher uncertainty with regard
to longevity may spend more on health than countries where individuals face less uncertainty.
Second, such a feedback would likely occur through the political process, in analogy to the feed-
back relationship found by Zweifel et al. [2005]. But then, the debate revolves around the health
share in the GDP (HCE/GDP) rather than HCE itself. This calls for entering (HCE/GDP)
as a regressor. However, the Durbin-Wu-Hausman test (Durbin [1954], Wu [1973], Hausman
[1978]) for endogeneity does not reject the null hypothesis of exogeneity of (HCE/GDP )−5 as
well as of HCE−5 at the one percent level. Third, immediate effects of nonmedical inputs on
the dependent variable are unlikely. Alcohol consumption, for instance, does not reduce time
to death immediately but rather over the course of years. Thus, lifestyle variables are lagged 10
years. Medical inputs are lagged 5 years on the grounds that technological change in medicine
occurs at such a rapid pace that interventions farther back in one’s lifetime are not relevant
for the variability of health status anymore. Fourth, squared variables were included to permit
variable elasticities. They proved nonsignificant, however. The choice of variables is based on
the empirical findings of the literature review in Section 2. Due to data availability, only the
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following are included in the model that will be estimated using both RE and FE (predicted











+ ci + uit (7)
All variables are in logarithms, permitting coefficients to be interpretable as elasticities. In this
way the coefficients can be easily interpreted as elasticities.
• GINI: Gini coefficient of the distribution of length of life, calculated according to eq. (5).
• HCE−5: HCE per capita in 1,000 USD, measured at purchasing power parity. Devoting
more resources to health-care is expected to enhance control over health status, reflected
in a lowered value of GINI.
• HOSPBED−5: Number of hospital beds per 1,000 inhabitants. With hospital stays
usually triggered by severe health problems that might jeopardize survival, better access
to hospital beds is predicted to enhance control and hence lower GINI.
• GDP−10: GDP per capita in 1,000 USD, measured at purchasing power parity. This
variable reflects two things. First, control over health status is quite likely a normal good,
the demand for which increases with average income, ceteris paribus. Second, average
income is importantly determined by labor productivity. To the extent that non-market
productivity develops in a similar way, a higher per-capita GDP reflects a population that
is better able to control their health status, resulting in a lower GINI value.
• POP65−10: Percent of population over 65. Individuals past 65, being in retirement,
may at first have more time available to invest in stabilizing their health status. This
advantage probably is balanced after a few years by a decreasing effectiveness of their
efforts, resulting in an increasing variability of health status and hence GINI. On the
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other hand, a high share of individuals reaching age 65 or more ten years previously
may indicate a population “purged” of individuals unable to avoid large negative shocks
to their health status, thus composed of survivors who successfully control their health
status. Therefore, the sign of POP65 is ambiguous.
• ALC−10: Alcohol consumption in liter per capita. While alcohol consumption is associ-
ated with a reduced remaining life expectancy, its effect on its variability is not established.
Still, one may argue that it undermines individuals’ capability to stabilize health. The
predicted effect on GINI is therefore positive.
Data for the dependent variable is obtained from the Human Mortality Database [2008]
(HMD), and for the regressors from the OECD [2007]. The latter source is known for its
problems. One of them is national differences with regard to the delimitation of the healthcare
sector, resulting in different baskets of benefits, another, the lack of comparability and precision
of healthcare deflators. The first difficulty is avoided by controlling for unobserved country-
specific effects, the second, by expressing healthcare expenditure in USD purchasing power
parity.
Spanning the years 1960 to 2004 and including 24 OECD countries (Greece, Ireland, Mexico,
Poland, South Korea, and Turkey had to be excluded entirely), the data set comprises 1,080
observations on the dependent variable, GINI. However, due to missing values in the OECD
health data base, the panel is unbalanced.
The descriptive statistics are summarized in Table 1 below. The focus on industrial countries
explains the low overall mean of the GINI value already in 1960. HCE steadily increased over
time, reaching a mean of 2,210 USD in the year 2000. Interestingly the number of hospital beds
per 1,000 inhabitants declined. This is mainly due to data availability, since those countries
with a low number of hospital beds (such as Czech Republic, Portugal, and Spain) reported
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their figures only recently. The share of population over 65 confirms the demographic trend
of an aging population, and the decrease of alcohol consumption between the period 1980 and
2000 points to a healthier lifestyle in industrial countries.
[Table 1 about here]
5 Estimation results
5.1 Variability of life expectancy
This section is devoted to the econometric estimation of eq. (7). Both the RE and FE
estimation were found to suffer from positive serial correlation. One way to deal with serial cor-
relation is to estimate RE and FE with a first-order autoregressive error term [AR(1) process].5
When reestimating eq. (7) accordingly both for the total population and separately for the two
genders, the Hausman test prefers RE over FE throughout at the five percent significance level.
Thus only the results of the RE estimations are presented in Table 2 below.
[Table 2 about here]
The results are similar across the three estimations. However, the effect of HCE−5 on the
Gini coefficient of length of life is estimated to be higher for females than for males, suggesting
that medical inputs are more effective in the reduction of health variability in the female popu-
lation. By way of contrast, it is there that HOSPBED−5 fails to attain statistical significance.
More surprisingly still, HOSPBED−5 is positively related to the Gini coefficient in two out of
5 The AR(1) process calls for a two step procedure. First, the model is estimated using FE. Second, the
autocorrelation coefficient, ρ, is estimated from the residuals through ûit = ρûi,t−1 + it. Finally, the
transformed model y∗it = βx
∗
it + ci + uit can be estimated either with FE or RE, where y
∗
it = yit − ρyi,t−1
and x∗it = xit − ρxi,t−1 (for further details see Greene [2008], ch. 19). Another way to deal with serial
correlation is to estimate the model using OLS but to correct the standard errors. The results are similar
to AR(1) estimation and relegated to the Appendix (see Table 7 in the Appendix).
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three estimations, contradicting the theoretical expectations stated in Section 4. There are two
possible explanations. First, there may be reverse causality, with countries characterized by
high variability in length of life investing in hospital beds. However, the Durbin-Wu-Hausman
test does not point to endogeneity of HOSPBED−5. Second, the variability-reducing effect of
HOSPBED−5 could already be captured in the variable HCE−5. Hospitals might be assigned
the very sick where not much can be done to regain control over health status. This argument
is supported by an estimation excluding HOSPBED−5 [column (4)]. There, the estimated
elasticity of HCE−5 is markedly higher in absolute value.
As expected, GDP−10 has a reducing impact on the variability of longevity, with a ceteris
paribus elasticity of 0.03, which however is lower than the 0.05 of HCE−5. For instance, a
10 percent higher GDP per capita is estimated to lower variability of longevity by 0.3 percent
compared to almost 0.5 percent due to HCE. Next, the variable POP65−10 contributes to a
reduction rather than increase of the dependent variable. Apparently the “survival of the fittest”
effect exceeds the “loss of control over health” effect. However, the variable is only significant
on the 10 percent level in two out of four estimations. Alcohol consumption is significant
across all four estimations. A reduction by 10 percent results in a 0.3 percent decrease of the
Gini coefficient ten years later. To sum up, both medical and nonmedical inputs reduce the
variability of life expectancy. Finally, note that a double-logarithmic formulation necessarily
implies decreasing marginal returns if the estimated elasticity is negative6.
A major drawback of estimations (1) to (3) in Table 2 is the high number of missing values,
mainly due to HOSPBED−5. Its exclusion from (4) thus serves to check for the importance
of missing values. First, the Hausman test again prefers the RE over FE specification. Second,
estimated coefficients remain stable (with the exception of POP65−10 being no longer signifi-











= 0 by assumption. Solving for ∂
2Y
∂X2








> 0, i.e. decreasing marginal returns in the present context.
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cant). Third, HCE per capita continues to have a higher impact on the Gini coefficient than
GDP per capita, an indicator of nonmedical inputs.
5.2 Life expectancy itself
Equation (7) was essentially borrowed from Zweifel et al. [2005] (see Section 2.1 above),
where remaining life expectancy at age 65 constituted the dependent variable. At the end of
Section 3, the tentative hypothesis was stated that the same factors determining the expected
value of health also influences its variability, eq. (7) should perform well in explaining life
expectancy although the present study uses HMD in addition to OECD data. Still, a few
adjustments are necessary to ensure comparability with Zweifel et al. [2005]. First, the variable
GDP is treated as reflecting a budget constraint there, which calls for replacing GDP−10 by
GDP without a lag. Second, HOSPBED−5 is excluded7. Third, specification tests preferred
a quadratic functional form without logarithms.
[Table 3 about here]
Table 3 exhibits only the RE results since for all three estimations the Hausman test again
prefers RE over FE. In col. (1), life expectancy at birth for both genders is the dependent
variable, whereas in cols. (2) and (3), it is the gender-specific value at age 65. The effects of
GDP and HCE−5 are significant in all three specifications. For a comparison with Table 2,
elasticities evaluated at the means are provided (see the values in brackets of Table 3; values in
italics are copied from Tables 2 and 8). Three things are noteworthy. First, the same factors
that were found to decrease (increase) the variability of life expectancy indeed are estimated
to increase (decrease) its expected value. Second, whereas GDP is less effective than HCE in
reducing the variability of longevity, it is more effective in increasing its expected value (which
7 The variable also proved nonsignificant when included.
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is in accordance with most studies on the production of health). Third, HCE has decreasing
marginal returns both as an instrument for controlling variability of health status and enhancing
its expected value. However, the marginal effectiveness of nonmedical inputs seems to dominate
that of the medical ones in both respects.8
6 Conclusion
This study addresses an issue that seems to have been overlooked in health economics with
its exclusive focus on the determinants of the expected level of health. However, for risk-averse
individuals, variability of health also is important. This raises the question of how variability of
health status has developed over time and whether the finding of “flat-of-the-curve medicine”
(i.e. low marginal returns to healthcare expenditure) carries over. The Gini coefficient of life
expectancy serves as an indicator of uncertainty concerning health status. A value of zero
indicates that everyone dies at the same age, i.e. minimum variability. Between 1960 and 2004,
it decreased for all 24 OECD countries sampled, pointing to improved control over individuals’
health status. Next, the Gini coefficient is related to inputs to the production of health. Taking
account of hidden heterogeneity through a random effects specification and for first-order-
autocorrelation with the lagged residual, nonmedical inputs are found less important in reducing
the variability of health status than medical ones, measured by healthcare expenditure per
capita five years before. For comparison with the existing literature, a conventional production
function with the level of life expectancy is also estimated. The results replicate both the
findings with regard to the variability and (from earlier studies) the expected value of life
expectancy suggesting that medical inputs exhibit decreasing marginal returns.
8 From column (1) of Table 3, one obtains the critical value beyond which e(LE, HCE) decreases: ∂LE
∂HCE
=
0.747−2 ·0.157HCE = 0. This yields HCE=2.38 or 2,379 USD respectively. For women, one obtains 1,870
USD, and for men 2,468 USD. These values are in the same range as those in Zweifel et al. [2005].
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There are limitations to this study that need to be pointed out. First, the variability of
health status is only crudely measured by the Gini coefficient of life expectancy. Data at the
individual level such as quality-adjusted life years (QALYs) would be more informative. Second,
the macroeconomic approach severely constrains the choice of variables in the econometric
model. Additional determinants such as education, innovation in health care, and additional
lifestyle variables might not only influence the level of health but also its variability. Finally,
to derive possible welfare gains of a reduced variability of health status, the empirical model
needs to be related more closely to the theory of the production of health (e.g. to the modified
Grossman model by Picone et al. [1998]).
However, the finding that not only expected health status but also its variability can be in-
fluenced already has important implications. Reduced uncertainty about age at death likely has
been modifying the decisions especially of older individuals concerning savings, consumptions,
and the purchase of life and long-term care insurance. Quite generally, it helps risk-averse indi-
viduals to optimize lifetime consumption, permitting them to reduce precautionary saving (see
Palumbo [1999] but also Levhari and Mirman [1977]). To the extent that health care services
serve to improve control over health status, “flat-of-the-curve medicine” need not be wasteful.
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Appendix
Figure 1: Lorenz curves for length of life, Portugal
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Figure 2: Gini coefficients for the US, Japan, Italy, and Portugal, 1960-2004
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Figure 3: Gini coefficient and life expectancy for 1970 and 2003
Country codes: DE=Germany, PT=Portugal, SE=Sweden, UK=United Kingdom, US=United States
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Table 1: Descriptive statistics of variables, selected years
Variable Mean 1960 1980 2000 s.d.a N
GINI 0.12 0.14 0.12 0.10 0.02 1,080
HCE 1.20 0.01 0.70 2.21 1.02 835
HOSPBED 6.93 9.05 7.48 6.27 2.53 456
GDP 13.74 1.99 10.02 26.11 10.35 999
POP65 12.50 9.44 12.50 14.75 2.71 1,078
ALCOHOL 10.62 7.87 11.92 9.98 3.66 1,003
Note: See text for definitions
as.d.= Standard deviation
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Table 2: Determinants of the Gini coefficient for 24 OECD countries, 1960-2004
Explanatory Predicted Total Females Males Total
variable sign (1) (2) (3) (4)
HCE−5 - -0.0481*** -0.0518*** -0.0411*** -0.0544***
(0.0105) (0.0112) (0.0119) (0.0010)
HOSPBED−5 - 0.0483*** 0.0218 0.0587*** -
(0.0155) (0.0161) (0.0156)
GDP−10 - -0.0309** -0.0293** -0.0367** -0.0421***
(0.0138) (0.0147) (0.0167) (0.0129)
POP65−10 +/- -0.0555* -0.0642* -0.0414 -0.0204
(0.0326) (0.0341) (0.0338) (0.0337)
ALC−10 + 0.0359*** 0.0417*** 0.0702*** 0.0308***
(0.0126) (0.0132) (0.0126) (0.0106)
Constant -2.223*** -2.311*** -2.274*** -2.184***
(0.0967) (0.1010) (0.1030) (0.0815)
ρ 0.902 0.880 0.868 0.855
Observations 297 297 297 607
R2 0.887 0.882 0.878 0.891
*** p<0.01, ** p<0.05, * p<0.1
Notes: Standard errors are given in parentheses.
All variables are in natural logarithms.
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Table 3: Determinants of remaining life expectancy for 24 OECD countries
Age 65, Age 65,
At birth Females Males
(1) (2) (3)
HCE−5 0.7470* [0.012] 1.0810*** [0.066] 0.5430** [0.041]
(0.3930) -0.054a (0.2610) -0.056a (0.2540) -0.063a
HCE2−5 -0.1570** -0.2890*** -0.1100**
(0.0737) (0.0479) (0.0460)
GDP 0.3780*** [0.089] 0.0600** [0.059] 0.1560*** [0.190]
(0.0388) -0.042a (0.0259) -0.035a (0.0251) -0.042a
GDP2 -0.0048*** 0.0007* -0.0011***
(0.0006) (0.0004) (0.0004)
POP65−10 1.0060*** [0.161] 0.1900** [0.127] 0.6620*** [0.546]
(0.1330) -0.02a (0.0836) -0.049a (0.0898) -0.01a
POP652−10 -0.0366*** -0.0023 -0.0248***
(0.0053) (0.0033) (0.0036)
ALC−10 -0.3120*** [-0.039] -0.0326 [-0.017] -0.2630*** [-0.174]
(0.0865) 0.031a (0.0556) 0.034a (0.0564) -0.036a
ALC2−10 0.0031 0.0019 0.0056**
(0.0037) (0.0024) (0.0024)
Constant 66.811*** 14.393*** 9.787***
(0.7530) (0.5120) (0.5040)
ρ 0.925 0.924 0.864
Observations 461 433 462
R2 0.915 0.895 0.892
*** p<0.01, ** p<0.05, * p<0.1
Notes: Standard errors are given in parentheses.
Values in brackets are elasticities evaluated at the means.
aElasticity taken from corresponding col. of Tables 2 and 8.
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Table 4: Development of the Gini coefficient over time for 24 countries
Country 1960 1970 1980 1990 2004
Australia 0.1315 0.1294 0.1161 0.1061 0.0932
Austria 0.1478 0.1332 0.1199 0.1068 0.0951
Belgium 0.1368 0.127 0.1160 0.1066 0.0964
Canada 0.1388 0.1311 0.1181 0.1067 0.0963
Czech Republic 0.1264 0.1281 0.1193 0.1166 0.1009
Denmark 0.1211 0.1183 0.1142 0.1110 0.0992
Finland 0.1337 0.1239 0.1120 0.1098 0.0990
France 0.1377 0.1292 0.1196 0.1116 0.1004
Germany 0.1404 0.1299 0.1158 0.1037 0.0930
Hungary 0.1524 0.1403 0.1351 0.1364 0.1198
Iceland 0.1185 0.1185 0.1099 0.1045 0.0875
Italy 0.1528 0.1325 0.1135 0.1034 0.0897
Japan 0.1509 0.1186 0.1015 0.0942 0.0922
Luxembourg 0.1401 0.1362 0.1153 0.1096 0.0957
Netherlands 0.1162 0.1143 0.1063 0.1002 0.0914
New Zealand 0.1243 0.1242 0.1176 0.1125 0.0934
Norway 0.1188 0.1127 0.1060 0.1047 0.0916
Portugal 0.2071 0.1749 0.1340 0.1181 0.1002
Slovakia 0.1356 0.1351 0.1278 0.1255 0.1106
Spain 0.1542 0.1302 0.1099 0.1071 0.0936
Sweden 0.1144 0.1105 0.1048 0.0982 0.0877
Switzerland 0.1257 0.1179 0.1087 0.1032 0.0899
United Kingdom 0.1255 0.1213 0.1127 0.1053 0.0956
United States 0.1438 0.1409 0.1264 0.1204 0.1129
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Table 5: Development of the Gini coefficient over time for 24 countries, females
Country 1960 1970 1980 1990 2004
Australia 0.1187 0.1155 0.1012 0.0937 0.0828
Austria 0.1300 0.1154 0.1018 0.0909 0.0814
Belgium 0.1202 0.1119 0.1019 0.0934 0.0838
Canada 0.1234 0.1159 0.1045 0.0947 0.0877
Czech Republic 0.1109 0.1105 0.1020 0.0976 0.0848
Denmark 0.1107 0.1070 0.1038 0.1017 0.0907
Finland 0.1135 0.1018 0.0908 0.0897 0.0819
France 0.1213 0.1109 0.0990 0.0905 0.0837
Germany 0.1254 0.1142 0.1011 0.0904 0.0819
Hungary 0.1393 0.1238 0.1168 0.1143 0.1004
Iceland 0.1045 0.0945 0.0928 0.0930 0.0833
Italy 0.1385 0.1176 0.0982 0.0883 0.0784
Japan 0.1402 0.1066 0.0895 0.0819 0.0794
Luxembourg 0.1196 0.1216 0.1075 0.0977 0.0823
Netherlands 0.1050 0.1011 0.0942 0.0903 0.0848
New Zealand 0.1133 0.1106 0.1083 0.1000 0.0855
Norway 0.1045 0.0957 0.0901 0.0912 0.0825
Portugal 0.1906 0.1571 0.1145 0.0981 0.0825
Slovakia 0.1208 0.1159 0.1077 0.1024 0.0925
Spain 0.1413 0.1162 0.0953 0.0882 0.0772
Sweden 0.1043 0.0987 0.0921 0.0877 0.0800
Switzerland 0.1099 0.1017 0.0933 0.0880 0.0789
United Kingdom 0.1138 0.1102 0.1031 0.0961 0.0872
United States 0.1283 0.1248 0.1118 0.1063 0.1009
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Table 6: Development of the Gini coefficient over timefor 24 countries, males
Country 1960 1970 1980 1990 2004
Australia 0.1398 0.1375 0.1238 0.1139 0.0990
Austria 0.1620 0.1462 0.1328 0.1171 0.1040
Belgium 0.1493 0.1373 0.1241 0.1138 0.1028
Canada 0.1507 0.1412 0.1269 0.1132 0.1017
Czech Republic 0.1383 0.1394 0.1304 0.1263 0.1103
Denmark 0.1303 0.1266 0.1193 0.1156 0.1035
Finland 0.1490 0.1389 0.1235 0.1216 0.1098
France 0.1485 0.1404 0.1316 0.1242 0.1091
Germany 0.1529 0.1413 0.1257 0.1117 0.1006
Hungary 0.1641 0.1532 0.1468 0.1484 0.1299
Iceland 0.1310 0.1373 0.1224 0.1124 0.0893
Italy 0.1647 0.1439 0.1237 0.1132 0.0961
Japan 0.1589 0.1272 0.1095 0.1018 0.0981
Luxembourg 0.1572 0.1462 0.1184 0.1154 0.1031
Netherlands 0.1256 0.1236 0.1126 0.1044 0.0939
New Zealand 0.1319 0.1323 0.1220 0.1200 0.0975
Norway 0.1309 0.1252 0.1164 0.1122 0.0964
Portugal 0.2211 0.1896 0.1494 0.1319 0.1115
Slovakia 0.1486 0.1494 0.1424 0.1379 0.1205
Spain 0.1647 0.1417 0.1209 0.1203 0.1043
Sweden 0.1230 0.1191 0.1120 0.1040 0.0914
Switzerland 0.1386 0.1297 0.1185 0.1127 0.0971
United Kingdom 0.1324 0.1261 0.1159 0.1088 0.0999
United States 0.1552 0.1523 0.1370 0.1308 0.1206
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Table 7: Estimation of GINI with panel-corrected standard errors, FE specification
VARIABLES Coefficient z P> z
HCE−5 -0.0349 0.0150 0.0200
HOSPBED−5 0.0446 0.0196 0.0230
GDP−10 -0.0430 0.0176 0.0140
POP65−10 -0.0372 0.0249 0.1360
ALC−10 0.0716 0.0089 0.000
Australiad 0.0141 0.0195 0.4690
Belgiumd 0.0162 0.0053 0.0020
Canadad 0.0441 0.0189 0.0200
Switzerlandd -0.0476 0.0112 0.000
Czech Republicd -0.0435 0.0145 0.0030
Germanyd 0.0384 0.0031 0.000
Denmarkd 0.0636 0.0122 0.000
Finlandd 0.0136 0.0093 0.1440
Franced 0.0165 0.0061 0.0070
Hungaryd 0.1290 0.0095 0.000
Italyd -0.0294 0.0086 0.0010
Japand -0.0667 0.0144 0.000
Luxembourgd -0.0117 0.0130 0.3660
Netherlandsd -0.0255 0.0138 0.0650
Norwayd 0.0518 0.0138 0.000
Portugald 0.0536 0.0215 0.0120
Slovakiad 0.0366 0.0130 0.0050
Spaind -0.0308 0.0213 0.1480
United Kingdomd 0.0158 0.0138 0.2520
United Statesd 0.1910 0.0222 0.000
Constant -2.340 0.121 0.000
Observations 297
R-squared 0.965
Notes: Not included are Iceland, New Zealand, and Sweden.
(d) denotes country dummies.
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Table 8: GINI estimation excluding HOSPBED
Total Females Males
VARIABLES (1) (2) (3)
HCE−5 -0.0544*** -0.0560*** -0.0634***
(0.0100) (0.0111) (0.0121)
GDP−10 -0.0421*** -0.0354** -0.0422***
(0.0129) (0.0142) (0.0154)
POP65−10 -0.0204 -0.0486 -0.0069
(0.0337) (0.0359) (0.0375)
ALC−10 0.0308*** 0.0344*** 0.0364***
(0.0106) (0.0116) (0.0124)
Constant -2.184*** -2.276*** -2.159***
(0.0815) (0.0867) (0.0908)
ρ 0.855 0.829 0.811
Observations 607 607 607
R2 0.892 0.877 0.882
*** p<0.01, ** p<0.05, * p<0.1
Notes: Standard errors are given in parentheses
RE specification. The variables are in natural logarithms.
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Figure 4: Top and bottom five Gini coefficients for 1960 (ranks in parentheses)
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Figure 5: Top and bottom five Gini coefficients for 2003 (ranks in parentheses)
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